Sign In
Buy ABSI
Absci Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.190 |
| EPS Surprise | 5.00% |
| Revenue estimate | 1.256M |
| Revenue actual | 215K |
| Revenue Surprise | -82.89% |
| Release date | Mar 24, 2026 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.230 |
| EPS Surprise | -43.75% |
| Revenue estimate | 1.339M |
| Revenue actual | 650K |
| Revenue Surprise | -51.45% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.200 |
| EPS Surprise | -5.26% |
| Revenue estimate | 1.381M |
| Revenue actual | 378K |
| Revenue Surprise | -72.63% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.240 |
| EPS Surprise | -26.32% |
| Revenue estimate | 5.175M |
| Revenue actual | 593K |
| Revenue Surprise | -88.54% |
Last 4 Quarters for Absci
Below you can see how ABSI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $2.97 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.240 |
| EPS surprise | -26.32% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $2.91 |
| Aug 07, 2025 | $2.92 |
| Aug 08, 2025 | $2.84 |
| Aug 11, 2025 | $2.85 |
| Aug 12, 2025 | $2.97 |
| Aug 13, 2025 | $3.12 |
| Aug 14, 2025 | $3.00 |
| Aug 15, 2025 | $2.93 |
| Aug 18, 2025 | $2.83 |
| 4 days before | 2.06% |
| 4 days after | -4.71% |
| On release day | 5.05% |
| Change in period | -2.75% |
| Release date | Nov 12, 2025 |
| Price on release | $3.40 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.200 |
| EPS surprise | -5.26% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $3.59 |
| Nov 07, 2025 | $3.34 |
| Nov 10, 2025 | $3.32 |
| Nov 11, 2025 | $3.45 |
| Nov 12, 2025 | $3.40 |
| Nov 13, 2025 | $2.64 |
| Nov 14, 2025 | $2.82 |
| Nov 17, 2025 | $2.86 |
| Nov 18, 2025 | $2.84 |
| 4 days before | -5.29% |
| 4 days after | -16.47% |
| On release day | -22.35% |
| Change in period | -20.89% |
| Release date | Mar 24, 2026 |
| Price on release | $3.01 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.230 |
| EPS surprise | -43.75% |
| Date | Price |
|---|---|
| Mar 18, 2026 | $2.86 |
| Mar 19, 2026 | $3.08 |
| Mar 20, 2026 | $2.96 |
| Mar 23, 2026 | $2.93 |
| Mar 24, 2026 | $3.01 |
| Mar 25, 2026 | $2.92 |
| Mar 26, 2026 | $2.88 |
| Mar 27, 2026 | $2.78 |
| Mar 30, 2026 | $2.76 |
| 4 days before | 5.24% |
| 4 days after | -8.31% |
| On release day | -2.99% |
| Change in period | -3.50% |
| Release date | May 07, 2026 |
| Price on release | $5.75 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.190 |
| EPS surprise | 5.00% |
| Date | Price |
|---|---|
| May 01, 2026 | $4.92 |
| May 04, 2026 | $5.62 |
| May 05, 2026 | $5.61 |
| May 06, 2026 | $5.95 |
| May 07, 2026 | $5.75 |
| May 08, 2026 | $5.90 |
| May 11, 2026 | $5.78 |
| May 12, 2026 | $5.36 |
| May 13, 2026 | $5.30 |
| 4 days before | 16.87% |
| 4 days after | -7.83% |
| On release day | 2.61% |
| Change in period | 7.72% |
Absci Earnings Call Transcript Summary of Q1 2026
Absci provided a business update focused on progress of ABS-201 (anti-prolactin receptor antibody) and pipeline strategy. Key clinical milestones: Phase I/IIa HEADLINE (AGA) is on track — blinded preliminary safety, tolerability and SAD PK data expected next month (June 2026); an interim 13-week directional proof-of-concept (hair regrowth) readout is planned for H2 2026; full 26-week proof-of-concept readout expected early 2027. Preliminary PK modeling from SAD cohorts supports a low-frequency dosing paradigm (targeting 2–3 injections over ~6 months; dosing possibly every ~8 weeks). Absci intends to start a Phase II endometriosis trial in Q4 2026, contingent on data and regulatory review, and has formed an Endometriosis Clinical Advisory Board. The company added ABS-202 (another anti-prolactin receptor program) targeting an inflammatory/autoimmune indication and is expanding its prolactin-focused pipeline. Absci is deprioritizing oncology programs (ABS-301, ABS-501) to concentrate resources on higher ROI indications (AGA, endometriosis, I&I) and potential partnering opportunities. Commercial view: company-reported market research indicates a potential U.S. TAM >$25B for AGA under a target product profile (TPP) of multi-year durability after a few injections; endometriosis peak sales potential estimated >$4B. Financials: Q1 revenue $0.2M; R&D $19.3M; SG&A $9.1M; cash, cash equivalents and marketable securities $125.7M as of 3/31/26, which management expects will fund operations into H1 2028. Strategic emphasis on leveraging Absci’s AI-native platform and agentic AI workflows to drive R&D productivity and cost efficiencies; pursuing selective partnering and non-dilutive deals for early assets.
